Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
06/21/2017 06/22/2017 06/23/2017 06/26/2017 06/27/2017 Date
290.4(c) 292.2(c) 294(c) 294.3(c) 287.9 Last
4 302 695 2 842 825 3 182 920 2 841 050 2 821 623 Volume
-0.03% +0.62% +0.62% +0.10% -2.17% Change
More quotes
Financials ( DKK)
Sales 2017 115 848 M
EBIT 2017 50 067 M
Net income 2017 38 091 M
Finance 2017 18 034 M
Yield 2017 2,62%
Sales 2018 121 464 M
EBIT 2018 52 238 M
Net income 2018 41 022 M
Finance 2018 17 096 M
Yield 2018 2,85%
P/E ratio 2017 19,12
P/E ratio 2018 17,34
EV / Sales2017 4,83x
EV / Sales2018 4,61x
Capitalization 577 583 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
06/26 NOVO NORDISK A/S : - Share repurchase programme
06/24 NOVO NORDISK A/S : Announces Headline Results Of Semaglutide
06/24 NOVO NORDISK A/S : Novos Saxenda label to include cardio data
06/24 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
06/23 NOVO NORDISK A/S : rapporterer op til 13,8% vægttab hos svært overvægtige mennes..
06/23 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
06/23 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
06/23 NOVO NORDISK A/S : CHMP endorses EU label update of Saxenda based on the LEADER ..
06/23 NOVO NORDISK A/S : CHMP adopts positive opinion for EU label update of Victoza® ..
06/22 NOVO NORDISK A/S : Tresiba® demonstrated no increased risk of major cardiovascul..
More news
Sector news : Pharmaceuticals - NEC
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
More sector news : Pharmaceuticals - NEC
Latest Tweets
01:05pNovo Nordisk A/S $NVO Upgraded by Zacks Investment Research to “Buy”  
06/26Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase .. 
06/26Cpcm LLC Holds Position in Novo Nordisk A/S $NVO  
06/24Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase ..
6
06/23Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase ..
1
More tweets
Qtime:40
News from SeekingAlpha
06/23 Novo to investigate weight loss effect of GLP-1 analogue semaglutide, late-st..
06/22 JUNE BUYS : The 16 Stocks Added To My Fund
06/22 NVO (NVO) Investor Presentation - Slideshow
06/20 FDA Ad Comm backs CV risk claim for Novo's Victoza; shares ahead 1% after hou..
06/18 SANOFI : A Good Bet On Pharma
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 285  DKK
Spread / Average Target -3,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S15.43%86 701
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER4.80%203 487
MERCK AND COMPANY11.98%180 958
More Results